NCT01851499

Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain

Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: Danish Pain Research Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized, double-blinded, placebo-controlled, parallel group study of ultramicronized PEA (Normast)600 mg x 2 daily or corresponding placebo with a week of baseline period followed by 1 x 12 weeks treatment period.

Detailed description

Study design: Randomized, double-blinded, placebo-controlled, parallel, multi-center study of ultramicronized PEA (Normast)with a week of baseline period followed by 1 x 12 weeks treatment period. Methodology: Given Normast 600mg x 2 daily or corresponding placebo and kept on that dose for 12 weeks.

Conditions

• Neuropathic Pain
• Spinal Cord Injury

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Ultramicronized PEA (Normast)	600 mg

Timeline

• Start date: 2013-05-01
• Primary completion: 2015-05-01
• Completion: 2015-10-01
• First posted: 2013-05-10
• Last updated: 2015-10-20

Locations

2 sites across 1 country: Denmark